Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer

Oncogene

Volumn 33, Issue 37, 2014, Pages 4579-4588

  Wong, P P ^a   Yeoh, C C ^a   Ahmad, A S ^a   Chelala, C ^a   Gillett, C ^b   Speirs, V ^c   Jones, J L ^a   Hurst, H C ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR ALPHA; MAGEA2 PROTEIN, HUMAN; MELANOMA ANTIGEN; PROTEIN P53; TAMOXIFEN; TP53 PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL; ARTICLE; BREAST TUMOR; CANCER TRANSPLANTATION; CELL NUCLEUS; CELL PROLIFERATION; CHEMISTRY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEPG2 CELL LINE; HUMAN; MCF 7 CELL LINE; METABOLISM; MOUSE; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; MCF-7 CELLS; MELANOMA-SPECIFIC ANTIGENS; MICE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; TAMOXIFEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896421871     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.45     Document Type: Article

References (35)

1. (EBCTCG) EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
2. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genom 2008; 9: 239.
3. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2: 101-115.
4. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9: 631-643.
5. Hughes-Davies L, Caldas C, Wishart GC. Tamoxifen: the drug that came in from the cold. Br J Cancer 2009; 101: 875-878.
6. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28: 509-518.
7. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-625.
8. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995; 182: 689-698.
9. Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 2008; 105: 1650-1655.
10. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009; 100: 2014-2021.
11. Doyle JM, Gao J, Wang J, Yang M, Potts PR. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol Cell 2010; 39: 963-974.
12. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 2006; 103: 11160-11165.
13. Yang B, O'Herrin SM, Wu J, Reagan-Shaw S, Ma Y, Bhat KM et al. MAGE-A, mMageb, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 2007; 67: 9954-9962.
14. Nardiello T, Jungbluth AA, Mei A, Diliberto M, Huang X, Dabrowski A et al. MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clin Cancer Res 2011; 17: 4309-4319.
15. Butt AJ, Sutherland RL, Musgrove EA. Live or let die: oestrogen regulation of survival signalling in endocrine response. Breast Cancer Res 2007; 9: 306.
16. Toillon RA, Chopin V, Jouy N, Fauquette W, Boilly B, Le Bourhis X. Normal breast epithelial cells induce p53-dependent apoptosis and p53-independent cell cycle arrest of breast cancer cells. Breast Cancer Res Treat 2002; 71: 269-280.
17. Sheikh MS, Li XS, Chen JC, Shao ZM, Ordonez JV, Fontana JA. Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 1994; 9: 3407-3415.
18. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003; 100: 8424-8429.
19. Maas RA, Bruning PF, Top B, Breedijk AJ, Peterse HL. Growth arrest associated changes of mRNA levels in breast cancer cells measured by semi-quantitative RTPCR: potential early indicators of treatment response. Cancer Lett 1995; 97: 107-116.
20. Brooks CL, Gu W. Ubiquitination phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 2003; 15: 164-171.
21. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008; 13: 454-463.
22. Laios I, Journe F, Laurent G, Nonclercq D, Toillon RA, Seo HS et al. Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens. J Steroid Biochem Mol Biol 2003; 87: 207-221.
23. Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P et al. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and highgrade breast cancers. PLoS One 2011; 6: e17876.
24. Marcar L, Maclaine NJ, Hupp TR, Meek DW. Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res 2010; 70: 10362-10370.
25. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993; 106: 1377-1388.
26. McDonnell DP, Wardell SE. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Curr Opin Pharmacol 2010; 10: 620-628.
27. Green KA, Carroll JS. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer 2007; 7: 713-722.
28. Grigoriadis A, Caballero OL, Hoek KS, da Silva L, Chen YT, Shin SJ et al. CT-X antigen expression in human breast cancer. Proc Natl Acad Sci USA 2009; 106: 13493-13498.
29. Markou A, Strati A, Malamos N, Georgoulias V, Lianidou ES. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clin Chem 2011; 57: 421-430.
30. Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J 2004; 23: 3051-3060.
31. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003; 144: 1032-1044.
32. Williams CM, Scibetta AG, Friedrich JK, Canosa M, Berlato C, Moss CH et al. AP-2gamma promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene. EMBO J 2009; 28: 3591-3601.
33. Fentiman IS, Christiaens MR, Paridaens R, Van Geel A, Rutgers E, Berner J et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer 2003; 39: 309-316.
34. Fentiman IS, van Zijl J, Karydas I, Chaudary MA, Margreiter R, Legrand C et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10850 comparing modified radical mastectomy with tumorectomy plus tamoxifen. Eur J Cancer 2003; 39: 300-308.
35. Maraqa L, Cummings M, Peter MB, Shaaban AM, Horgan K, Hanby AM et al. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen. Clin Cancer Res 2008; 14: 405-411.